Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU5416 in Metastatic Melanoma
NCT00006003Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2000
- Primary completion
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of semaxanib in melanoma, sponsored by National Cancer Institute. Started Jul 2000; status: terminated.
02
Drugs
semaxanib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00006003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006003.